Please assess the completion status of the following clinical trial:

Trial Title: VAccination to Improve Clinical outComes in Heart Failure Trial: a Feasibility Study (VACC-HeFT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults \> 18 years old~2. Able to give informed consent~3. Systolic or diastolic dysfunction~4. Previously or currently symptomatic heart failure~5. Stable on current heart failure drug therapy regimen for \> 30 days and no change in heart failure drug therapy regimen on day of enrollment~6. Hospitalization (for any reason) in last 12 months~7. Received influenza vaccination the prior season~Exclusion Criteria:~1. History of allergic reaction or adverse event to influenza vaccine~2. Documented severe allergy to egg products~3. Unwilling or unable to give consent~4. Moderate to severe acute febrile illness at baseline~5. Immunologic conditions that may affect immune responses per clinical judgment of the investigators~6. Use of immunosuppressants or immunomodulating therapies within 3 months of the study, including prednisone, cyclosporine, tacrolimus, methotrexate, azathioprine, mycophenolate mofetil, cyclophosphamide, and injectable interferons~7. Participation in a clinical trial within 30 days~8. Absence for more than 7 consecutive days during the surveillance period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard dose influenza vaccine (Type: ACTIVE_COMPARATOR): Standard dose (45ug) influenza vaccine will be administered intramuscularly
- High dose influenza vaccine (Type: ACTIVE_COMPARATOR): High dose (180ug) influenza vaccine will be administered intramuscularly

Based on this trial design, predict the completion outcome and termination type (if applicable).